Sales & Marketing Executive Brings Global Expertise in Global Channel Marketing
MIRAMAR, FL, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Mark J.
Prioletti to the Board of Directors. He is a highly experienced marketing and business professional with over 35 years of success
in the wireless communications industry for government, enterprise, and consumer segments in both the US and International markets.
Mr. Prioletti had a distinguished career at Motorola, leading Channel Marketing & Sales, New Program Development, Partnership and
Alliance Development to vastly expand the Motorola sales operations, which continually generated profitable revenue and growth for
both emerging markets and mature businesses. With exceptionally strong skills in marketing strategy and sales operation, Mr.
Prioletti adds valuable expertise to the Board of Directors.
“Mark Prioletti brings a wealth of sales and marketing experience and expertise to our Board of Directors,” said Joseph Moscato,
President & CEO of Generex Biotechnology. “In his long and successful career at Motorola, he was part of the mobile revolution that
changed the communications industry, launching and promoting paging and cellular technologies throughout the U.S., Europe, Asia,
and Australia. As we build Generex and the NuGenerex family of companies as an end-to-end solutions provider in healthcare, Mark
will provide valuable insight in consumer engagement and channel marketing, and we look forward to working with him on the
Board.”
Mr. Prioletti commented on his appointment to the Generex Board, “I am drawn to Joe’s vision to build Generex as an integrated
life science holdings company. The company has done an amazing job establishing the business foundation for a transformational
approach to healthcare. As in the cellular space, it is essential to embrace technology and engage customers across the spectrum of
the industry, from manufacturers to healthcare systems, to physicians and patients, and I hope to provide experience and guidance
to Joe and his management team as we grow Generex for the future.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid
diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused
on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy
network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with
any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid
placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact: Generex Biotechnology Corporation Joseph Moscato 646-599-6222 Todd Falls 1-800-391-6755 Extension 222 investor@generex.com
